325 related articles for article (PubMed ID: 23201823)
1. Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules.
Daly S; Rinewalt D; Fhied C; Basu S; Mahon B; Liptay MJ; Hong E; Chmielewski G; Yoder MA; Shah PN; Edell ES; Maldonado F; Bungum AO; Borgia JA
J Thorac Oncol; 2013 Jan; 8(1):31-6. PubMed ID: 23201823
[TBL] [Abstract][Full Text] [Related]
2. Value of circulating insulin-like growth factor-associated proteins for the detection of stage I non-small cell lung cancer.
Kubasiak JC; Seder CW; Pithadia R; Basu S; Fhied C; Phillips WW; Daly S; Shersher DD; Yoder MA; Chmielewski G; Edell ES; Maldonado F; Liptay MJ; Borgia JA
J Thorac Cardiovasc Surg; 2015 Mar; 149(3):727-34.e1-3; discussion 734. PubMed ID: 25312225
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis Biomarkers May Be Useful in the Management of Patients With Indeterminate Pulmonary Nodules.
Seder CW; Kubasiak JC; Pithadia R; Basu S; Fhied C; Tarhoni I; Davila E; Alnajjar H; Chmielewski GW; Warren WH; Liptay MJ; Borgia JA
Ann Thorac Surg; 2015 Aug; 100(2):429-36. PubMed ID: 26138771
[TBL] [Abstract][Full Text] [Related]
4. Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer.
Massion PP; Healey GF; Peek LJ; Fredericks L; Sewell HF; Murray A; Robertson JF
J Thorac Oncol; 2017 Mar; 12(3):578-584. PubMed ID: 27615397
[TBL] [Abstract][Full Text] [Related]
5. Combining serum miRNAs, CEA, and CYFRA21-1 with imaging and clinical features to distinguish benign and malignant pulmonary nodules: a pilot study : Xianfeng Li et al.: Combining biomarker, imaging, and clinical features to distinguish pulmonary nodules.
Li X; Zhang Q; Jin X; Cao L
World J Surg Oncol; 2017 May; 15(1):107. PubMed ID: 28545454
[TBL] [Abstract][Full Text] [Related]
6. [Value of Combined Detection of Cytokines and Tumor Markers in the
Differential Diagnosis of Benign and Malignant Solitary Pulmonary Nodules].
Shi J; Liu X; Ming Z; Li W; Lv X; Yang X; Wang Y; Zhang M; Yang S
Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):426-433. PubMed ID: 34157802
[TBL] [Abstract][Full Text] [Related]
7. DNA methylation of PTGER4 in peripheral blood plasma helps to distinguish between lung cancer, benign pulmonary nodules and chronic obstructive pulmonary disease patients.
Schotten LM; Darwiche K; Seweryn M; Yildiz V; Kneuertz PJ; Eberhardt WEE; Eisenmann S; Welter S; Sisson BE; Pietrzak M; Wiesweg M; Ploenes T; Hager T; He K; Freitag L; Aigner C; Taube C; Oezkan F
Eur J Cancer; 2021 Apr; 147():142-150. PubMed ID: 33662689
[TBL] [Abstract][Full Text] [Related]
8. Clinical Utility of a Plasma Protein Classifier for Indeterminate Lung Nodules.
Vachani A; Hammoud Z; Springmeyer S; Cohen N; Nguyen D; Williamson C; Starnes S; Hunsucker S; Law S; Li XJ; Porter A; Kearney P
Lung; 2015 Dec; 193(6):1023-7. PubMed ID: 26376647
[TBL] [Abstract][Full Text] [Related]
9. A Gene Expression Classifier from Whole Blood Distinguishes Benign from Malignant Lung Nodules Detected by Low-Dose CT.
Kossenkov AV; Qureshi R; Dawany NB; Wickramasinghe J; Liu Q; Majumdar RS; Chang C; Widura S; Kumar T; Horng WH; Konnisto E; Criner G; Tsay JJ; Pass H; Yendamuri S; Vachani A; Bauer T; Nam B; Rom WN; Showe MK; Showe LC
Cancer Res; 2019 Jan; 79(1):263-273. PubMed ID: 30487137
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography in the diagnostic work-up of screening-detected lung nodules.
Veronesi G; Travaini LL; Maisonneuve P; Rampinelli C; Bertolotti R; Spaggiari L; Bellomi M; Paganelli G
Eur Respir J; 2015 Feb; 45(2):501-10. PubMed ID: 25261326
[TBL] [Abstract][Full Text] [Related]
11. Establishment of a multi-analyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer.
Borgia JA; Basu S; Faber LP; Kim AW; Coon JS; Kaiser-Walters KA; Fhied C; Thomas S; Rouhi O; Warren WH; Bonomi P; Liptay MJ
J Thorac Oncol; 2009 Mar; 4(3):338-47. PubMed ID: 19190517
[TBL] [Abstract][Full Text] [Related]
12. Sputum microRNA biomarkers for identifying lung cancer in indeterminate solitary pulmonary nodules.
Xing L; Su J; Guarnera MA; Zhang H; Cai L; Zhou R; Stass SA; Jiang F
Clin Cancer Res; 2015 Jan; 21(2):484-9. PubMed ID: 25593345
[TBL] [Abstract][Full Text] [Related]
13. Predicting Malignancy Risk of Screen-Detected Lung Nodules-Mean Diameter or Volume.
Tammemagi M; Ritchie AJ; Atkar-Khattra S; Dougherty B; Sanghera C; Mayo JR; Yuan R; Manos D; McWilliams AM; Schmidt H; Gingras M; Pasian S; Stewart L; Tsai S; Seely JM; Burrowes P; Bhatia R; Haider EA; Boylan C; Jacobs C; van Ginneken B; Tsao MS; Lam S;
J Thorac Oncol; 2019 Feb; 14(2):203-211. PubMed ID: 30368011
[TBL] [Abstract][Full Text] [Related]
14. A classifier integrating plasma biomarkers and radiological characteristics for distinguishing malignant from benign pulmonary nodules.
Lin Y; Leng Q; Jiang Z; Guarnera MA; Zhou Y; Chen X; Wang H; Zhou W; Cai L; Fang H; Li J; Jin H; Wang L; Yi S; Lu W; Evers D; Fowle CB; Su Y; Jiang F
Int J Cancer; 2017 Sep; 141(6):1240-1248. PubMed ID: 28580707
[TBL] [Abstract][Full Text] [Related]
15. [Establishment and Verification of A Novel Predictive Model of Malignancy
for Non-solid Pulmonary Nodules].
Xiao F; Yu Q; Zhang Z; Liu D; Liang C
Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):26-33. PubMed ID: 30674390
[TBL] [Abstract][Full Text] [Related]
16. A prediction model based on DNA methylation biomarkers and radiological characteristics for identifying malignant from benign pulmonary nodules.
Xing W; Sun H; Yan C; Zhao C; Wang D; Li M; Ma J
BMC Cancer; 2021 Mar; 21(1):263. PubMed ID: 33691657
[TBL] [Abstract][Full Text] [Related]
17. Distinguishing patients with stage I lung cancer versus control individuals using serum mass profiling.
Hanas JS; Peyton MD; Lerner MR; Lightfoot SA; Deb SJ; Hanas RJ; Vu NT; Kupiec TC; Stowell DE; Brackett DJ; Dubinett SM; Hocker JR
Cancer Invest; 2014 May; 32(4):136-43. PubMed ID: 24579933
[TBL] [Abstract][Full Text] [Related]
18. Projected outcomes using different nodule sizes to define a positive CT lung cancer screening examination.
Gierada DS; Pinsky P; Nath H; Chiles C; Duan F; Aberle DR
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25326638
[TBL] [Abstract][Full Text] [Related]
19. A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer.
Ajona D; Remirez A; Sainz C; Bertolo C; Gonzalez A; Varo N; Lozano MD; Zulueta JJ; Mesa-Guzman M; C Martin A; Perez-Palacios R; Perez-Gracia JL; Massion PP; Montuenga LM; Pio R
Transl Res; 2021 Jul; 233():77-91. PubMed ID: 33618009
[TBL] [Abstract][Full Text] [Related]
20. Validation of a multiprotein plasma classifier to identify benign lung nodules.
Vachani A; Pass HI; Rom WN; Midthun DE; Edell ES; Laviolette M; Li XJ; Fong PY; Hunsucker SW; Hayward C; Mazzone PJ; Madtes DK; Miller YE; Walker MG; Shi J; Kearney P; Fang KC; Massion PP
J Thorac Oncol; 2015 Apr; 10(4):629-37. PubMed ID: 25590604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
